Shu-Wen Lin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7152484/publications.pdf

Version: 2024-02-01

54 papers	903 citations	18 h-index	27 g-index
54	54	54	1411
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Impact of high plasma concentrations of linezolid in Taiwanese adult patients— therapeutic drug monitoring in improving adverse drug reactions. Journal of the Formosan Medical Association, 2021, 120, 466-475.	1.7	19
2	Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort Study. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	4
3	Influenza vaccination and the risk of COVID-19 infection and severe illness in older adults in the United States. Scientific Reports, 2021, 11, 11025.	3.3	36
4	Impact of Efavirenz Mid-dose Plasma Concentration on Long-Term Weight Change Among Virologically Suppressed People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 834-841.	2.1	8
5	Shortâ€course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide. Journal of the International AIDS Society, 2021, 24, e25844.	3.0	10
6	Effectiveness of half-a-tablet efavirenz plus 2 nucleos(t)ide reverse-transcriptase inhibitors as maintenance therapy with the guidance of therapeutic drug monitoring among virologically suppressed HIV-positive patients: A prospective study. Journal of Microbiology, Immunology and Infection, 2020, 53, 60-68.	3.1	4
7	Therapeutic drug monitoring of the teicoplanin trough level after the loading doses in patients receiving venoarterial extracorporeal membrane oxygenation. Journal of the Formosan Medical Association, 2020, 119, 1086-1092.	1.7	8
8	Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression. Journal of Microbiology, Immunology and Infection, 2020, 54, 944-951.	3.1	0
9	Metabolomics analysis of plasma reveals voriconazole-induced hepatotoxicity is associated with oxidative stress. Toxicology and Applied Pharmacology, 2020, 403, 115157.	2.8	8
10	CD4 response of QuantiFERON-TB Gold Plus for positive consistency of latent tuberculosis infection in patients on dialysis. Scientific Reports, 2020, 10, 21367.	3.3	4
11	Clinical pharmacy service and international collaboration: Model and experience from a medical center in Taiwan. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 959.	1.0	3
12	Implementation and outcomes of a therapeutic drug monitoring program for antifungal and antiretroviral agents in a tertiary medical center in Taiwan. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 905.	1.0	2
13	Latent Tuberculosis Infection Increases in Kidney Transplantation Recipients Compared With Transplantation Candidates: A Neglected Perspective in Tuberculosis Control. Clinical Infectious Diseases, 2020, 71, 914-923.	5.8	13
14	Human Breathomics Database. Database: the Journal of Biological Databases and Curation, 2020, 2020, .	3.0	37
15	Factors associated with treatment duration and recurrence rate of complicated mastitis. Journal of Microbiology, Immunology and Infection, 2020, 53, 875-881.	3.1	5
16	Metabolomics Investigation of Voriconazole-Induced Hepatotoxicity in Mice. Chemical Research in Toxicology, 2019, 32, 1840-1849.	3.3	13
17	<p>Augmented renal clearance is associated with inadequate antibiotic pharmacokinetic/pharmacodynamic target in Asian ICU population: a prospective observational study</p> . Infection and Drug Resistance, 2019, Volume 12, 2531-2541.	2.7	30
18	Development and Validation of a Risk Scoring System for Cephamycin-Associated Hemorrhagic Events. Scientific Reports, 2019, 9, 12905.	3.3	3

#	Article	IF	CITATIONS
19	Isoniazid Concentration and NAT2 Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI. Journal of Clinical Medicine, 2019, 8, 812.	2.4	15
20	Early linezolid-associated lactic acidosis in a patient with Child's class C liver cirrhosis and end stage renal disease. Journal of Infection and Chemotherapy, 2018, 24, 841-844.	1.7	8
21	Identification of potential sphingomyelin markers for the estimation of hematocrit in dried blood spots via a lipidomic strategy. Analytica Chimica Acta, 2018, 1003, 34-41.	5.4	15
22	Survival in Patients with Candida glabrata Bloodstream Infection Is Associated with Fluconazole Dose. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	11
23	Safety of high-dose daptomycin in patients with severe renal impairment. Therapeutics and Clinical Risk Management, 2018, Volume 14, 493-499.	2.0	12
24	The ratio of pre-dialysis vancomycin trough serum concentration to minimum inhibitory concentration is associated with treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia. PLoS ONE, 2018, 13, e0193585.	2.5	18
25	Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients. Journal of Microbiology, Immunology and Infection, 2017, 50, 595-603.	3.1	12
26	Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study. Journal of Microbiology, Immunology and Infection, 2017, 50, 789-797.	3.1	4
27	An on-spot internal standard addition approach for accurately determining colistin A and colistin B in dried blood spots using ultra high-performance liquid chromatography–tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2017, 145, 783-793.	2.8	4
28	Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy. Scientific Reports, 2017, 7, 16187.	3.3	8
29	Rifamycin SV MMX for the treatment of traveler's diarrhea. Expert Opinion on Pharmacotherapy, 2017, 18, 1269-1277.	1.8	3
30	Estimation and Correction of the Blood Volume Variations of Dried Blood Spots Using a Postcolumn Infused-Internal Standard Strategy with LC-Electrospray Ionization-MS. Analytical Chemistry, 2016, 88, 6457-6464.	6. 5	19
31	Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study. PLoS ONE, 2016, 11, e0158407.	2.5	30
32	Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy. PLoS ONE, 2015, 10, e0137660.	2.5	11
33	Presence of Tablet Remnants of Nevirapine Extended-Release in Stools and Its Impact on Virological Outcome in HIV-1-Infected Patients: A Prospective Cohort Study. PLoS ONE, 2015, 10, e0140574.	2.5	2
34	Development and validation of a high-performance liquid chromatography-fluorescence detection method for the accurate quantification of colistin in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 980, 48-54.	2.3	31
35	Development and application of a comparative fatty acid analysis method to investigate voriconazole-induced hepatotoxicity. Clinica Chimica Acta, 2015, 438, 126-134.	1.1	11
36	Therapeutic Drug Monitoring and Pharmacogenetic Study of HIV-Infected Ethnic Chinese Receiving Efavirenz-Containing Antiretroviral Therapy with or without Rifampicin-Based Anti-Tuberculous Therapy. PLoS ONE, 2014, 9, e88497.	2.5	24

#	Article	IF	CITATIONS
37	Multicenter Study of Trimethoprim/Sulfamethoxazole-Related Hepatotoxicity: Incidence and Associated Factors among HIV-Infected Patients Treated for Pneumocystis jirovecii Pneumonia. PLoS ONE, 2014, 9, e106141.	2.5	29
38	Effectiveness of a reduced dose of efavirenz plus 2 NRTIs as maintenance antiretroviral therapy with the guidance of therapeutic drug monitoring. Journal of the International AIDS Society, 2014, 17, 19524.	3.0	6
39	Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia. Expert Review of Anti-Infective Therapy, 2014, 12, 401-417.	4.4	12
40	Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan. International Journal of Infectious Diseases, 2014, 29, 12-17.	3.3	10
41	Sheltering Effect and Indirect Pathogenesis of Carbapenem-Resistant Acinetobacter baumannii in Polymicrobial Infection. Antimicrobial Agents and Chemotherapy, 2014, 58, 3983-3990.	3.2	35
42	Comparison of warfarin therapy clinical outcomes following implementation of an automated mobile phone-based critical laboratory value text alert system. BMC Medical Genomics, 2014, 7, S13.	1.5	12
43	Simultaneous quantification of antimicrobial agents for multidrug-resistant bacterial infections in human plasma by ultra-high-pressure liquid chromatography–tandem mass spectrometry. Talanta, 2013, 116, 593-603.	5.5	72
44	Effectiveness of Education Programs About Oral Antibiotic Suspensions in Pediatric Outpatient Services. Pediatrics and Neonatology, 2013, 54, 34-42.	0.9	25
45	Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study. Journal of Antimicrobial Chemotherapy, 2013, 68, 922-926.	3.0	42
46	Simultaneous determination of triazole antifungal drugs in human plasma by sweeping-micellar electrokinetic chromatography. Analytical and Bioanalytical Chemistry, 2012, 404, 217-228.	3.7	17
47	Rapid and sensitive determination of posaconazole in patient plasma by capillary electrophoresis with field-amplified sample stacking. Journal of Chromatography A, 2012, 1226, 48-54.	3.7	28
48	Using sweeping-micellar electrokinetic chromatography to determine voriconazole in patient plasma. Talanta, 2010, 82, 653-659.	5.5	17
49	Do We Still Need Leadâ€in Dosing of Nevirapine in HIVâ€Infected Patients Who Are Receiving Rifampicinâ€Containing Antituberculous Therapy?. Clinical Infectious Diseases, 2009, 49, 1452-1453.	5.8	2
50	Impact of <i>mecA</i> Gene Testing and Intervention by Infectious Disease Clinical Pharmacists on Time to Optimal Antimicrobial Therapy for <i>Staphylococcus aureus</i> Bacteremia at a University Hospital. Journal of Clinical Microbiology, 2008, 46, 2381-2383.	3.9	52
51	Survey of pharmacist collaborative drug therapy management in hospitals. American Journal of Health-System Pharmacy, 2006, 63, 2489-2499.	1.0	23
52	Effect of Glucosamine on Glucose Control. Annals of Pharmacotherapy, 2006, 40, 694-698.	1.9	22
53	Dalbavancin: A New Option for the Treatment of Gram-Positive Infections. Annals of Pharmacotherapy, 2006, 40, 449-460.	1.9	34
54	Progress of Pharmacist Collaborative Practice: Status of State Laws and Regulations and Perceived Impact of Collaborative Practice. Journal of the American Pharmacists Association: JAPhA, 2003, 43, 503-510.	1.5	20